Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin (Q36629243)

15 August 2017

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin (English)

1 reference

15 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

10

Jos H Beijnen

1 reference

15 August 2017

11

Alwin D R Huitema

1 reference

15 August 2017

13

Jan H M Schellens

1 reference

15 August 2017

Lot A Devriese

1

1 reference

15 August 2017

Petronella Els O Witteveen

2

1 reference

15 August 2017

Jantien Wanders

3

1 reference

15 August 2017

Kenneth Law

4

1 reference

15 August 2017

Geoff Edwards

5

1 reference

15 August 2017

Larisa Reyderman

6

1 reference

15 August 2017

William Copalu

7

1 reference

15 August 2017

Fuping Peng

8

1 reference

15 August 2017

Serena Marchetti

9

1 reference

15 August 2017

Emile E Voest

12

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2013

1 reference

British Journal of Clinical Pharmacology

15 August 2017

1 reference

15 August 2017

75

1 reference

15 August 2017

2

1 reference

15 August 2017

507-515

1 reference

P-glycoprotein related drug interactions: clinical importance and a consideration of disease states

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Herb-drug interactions in oncology: focus on mechanisms of induction

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Drug interactions in oncology

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Pharmacokinetic interactions with rifampicin : clinical relevance

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Toxicity and response criteria of the Eastern Cooperative Oncology Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Prediction of creatinine clearance from serum creatinine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579265

Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use

20 September 2018

1 reference

12 December 2020

Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells

1 reference

12 December 2020

Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices

1 reference

12 December 2020

Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors

1 reference

12 December 2020

ECCO position challenged by European drug regulators

1 reference

12 December 2020

10.1111/J.1365-2125.2012.04381.X

Identifiers

DOI

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

22803519

1 reference